Targeted News Service

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
September 29, 2026

NEW BRUNSWICK, New Jersey, Sept. 29 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY(r) (nipocalimab-aahu) in generalized myasthenia gravis (gMG)

*

Spring House, Pa. (September 29, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new findings on IMAAVY(r) (nipoc . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form